Mymetics Corporation Logo

Mymetics Corporation

MYMX

(1.8)
Stock Price

0,00 USD

-11068% ROA

11.73% ROE

-0.03x PER

Market Cap.

276.927,06 USD

-99.39% DER

0% Yield

-3691.96% NPM

Mymetics Corporation Stock Analysis

Mymetics Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Mymetics Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (18.13%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-0x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-100%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROA

The stock's ROA (-2297.37%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Mymetics Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Mymetics Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Mymetics Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Mymetics Corporation Revenue
Year Revenue Growth
2000 126.704
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 468.449 100%
2008 65.000 -620.69%
2009 150.000 56.67%
2010 222.000 32.43%
2011 176.000 -26.14%
2012 0 0%
2013 4.381.000 100%
2014 2.399.000 -82.62%
2015 3.151.000 23.87%
2016 1.253.000 -151.48%
2017 1.515.000 17.29%
2018 75.000 -1920%
2019 111.000 32.43%
2020 35.000 -217.14%
2021 3.000 -1066.67%
2022 3.000 0%
2023 147.944 97.97%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Mymetics Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 483.281 100%
2002 1.879.256 74.28%
2003 1.260.919 -49.04%
2004 395.396 -218.9%
2005 314.083 -25.89%
2006 337.929 7.06%
2007 3.619.335 90.66%
2008 2.692.000 -34.45%
2009 6.364.000 57.7%
2010 3.083.000 -106.42%
2011 1.343.000 -129.56%
2012 1.616.000 16.89%
2013 657.000 -145.97%
2014 1.565.000 58.02%
2015 1.727.000 9.38%
2016 1.001.000 -72.53%
2017 2.130.000 53%
2018 1.217.000 -75.02%
2019 970.000 -25.46%
2020 1.055.000 8.06%
2021 975.000 -8.21%
2022 1.515.504 35.66%
2023 240.000 -531.46%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Mymetics Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 3.693.000 100%
2009 3.288.000 -12.32%
2010 4.148.000 20.73%
2011 0 0%
2012 1.386.000 100%
2013 1.390.000 0.29%
2014 1.358.000 -2.36%
2015 1.562.000 13.06%
2016 1.254.000 -24.56%
2017 1.175.000 -6.72%
2018 1.115.000 -5.38%
2019 1.064.000 -4.79%
2020 1.187.000 10.36%
2021 1.105.000 -7.42%
2022 1.331.000 16.98%
2023 1.420.000 6.27%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Mymetics Corporation EBITDA
Year EBITDA Growth
2000 -956.137
2001 -15.588.632 93.87%
2002 -2.963.737 -425.98%
2003 -2.541.690 -16.6%
2004 -1.254.794 -102.56%
2005 -1.038.501 -20.83%
2006 -787.240 -31.92%
2007 -6.006.849 86.89%
2008 -6.320.000 4.95%
2009 -7.888.000 19.88%
2010 -8.282.000 4.76%
2011 -2.715.000 -205.05%
2012 -2.999.000 9.47%
2013 14.930.000 120.09%
2014 -524.000 2949.24%
2015 -135.000 -288.15%
2016 -1.001.000 86.51%
2017 -1.792.000 44.14%
2018 -1.367.000 -31.09%
2019 -1.471.000 7.07%
2020 -1.407.000 -4.55%
2021 -1.960.000 28.21%
2022 -1.990.000 1.51%
2023 -3.184.000 37.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Mymetics Corporation Gross Profit
Year Gross Profit Growth
2000 126.704
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 468.449 100%
2008 65.000 -620.69%
2009 150.000 56.67%
2010 222.000 32.43%
2011 176.000 -26.14%
2012 -1.616.000 110.89%
2013 3.724.000 143.39%
2014 834.000 -346.52%
2015 1.424.000 41.43%
2016 252.001 -465.08%
2017 -615.000 140.98%
2018 -1.142.000 46.15%
2019 -859.000 -32.95%
2020 -1.020.000 15.78%
2021 -972.000 -4.94%
2022 -1.439.000 32.45%
2023 -1.376.056 -4.57%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Mymetics Corporation Net Profit
Year Net Profit Growth
2000 -351.364
2001 -15.727.997 97.77%
2002 -3.625.098 -333.86%
2003 -2.781.487 -30.33%
2004 -1.423.722 -95.37%
2005 -1.246.202 -14.24%
2006 -984.997 -26.52%
2007 -5.624.134 82.49%
2008 -6.938.000 18.94%
2009 -10.186.000 31.89%
2010 -11.428.000 10.87%
2011 -10.539.000 -8.44%
2012 -6.111.000 -72.46%
2013 6.003.000 201.8%
2014 -3.256.000 284.37%
2015 -3.006.000 -8.32%
2016 -5.964.000 49.6%
2017 -4.112.000 -45.04%
2018 -4.172.000 1.44%
2019 -4.187.000 0.36%
2020 -4.158.000 -0.7%
2021 -7.152.000 41.86%
2022 -7.865.000 9.07%
2023 -4.456.000 -76.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Mymetics Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Mymetics Corporation Free Cashflow
Year Free Cashflow Growth
1998 -760.000
1999 540.000 240.74%
2000 -468.486 215.27%
2001 -2.003.932 76.62%
2002 -3.238.192 38.12%
2003 -1.769.893 -82.96%
2004 -801.858 -120.72%
2005 -394.293 -103.37%
2006 -1.031.216 61.76%
2007 -3.868.993 73.35%
2008 -7.801.000 50.4%
2009 -11.186.000 30.26%
2010 -7.898.000 -41.63%
2011 -5.252.000 -50.38%
2012 -4.960.000 -5.89%
2013 -4.453.000 -11.39%
2014 2.923.000 252.34%
2015 710.000 -311.69%
2016 -990.000 171.72%
2017 -2.488.000 60.21%
2018 -2.313.000 -7.57%
2019 -1.008.000 -129.46%
2020 -1.710.000 41.05%
2021 -1.708.000 -0.12%
2022 -1.689.000 -1.12%
2023 -335.000 -404.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Mymetics Corporation Operating Cashflow
Year Operating Cashflow Growth
1998 -760.000
1999 540.000 240.74%
2000 -468.486 215.27%
2001 -2.003.932 76.62%
2002 -3.238.192 38.12%
2003 -1.769.893 -82.96%
2004 -801.858 -120.72%
2005 -360.520 -122.42%
2006 -844.824 57.33%
2007 -4.014.397 78.96%
2008 -7.718.000 47.99%
2009 -11.046.000 30.13%
2010 -7.870.000 -40.36%
2011 -5.223.000 -50.68%
2012 -4.959.000 -5.32%
2013 -4.344.000 -14.16%
2014 2.968.000 246.36%
2015 730.000 -306.58%
2016 -987.000 173.96%
2017 -2.451.000 59.73%
2018 -2.313.000 -5.97%
2019 -972.000 -137.96%
2020 -1.696.000 42.69%
2021 -1.698.000 0.12%
2022 -1.687.000 -0.65%
2023 -335.000 -403.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Mymetics Corporation Capital Expenditure
Year Capital Expenditure Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 33.772 100%
2006 186.392 81.88%
2007 -145.404 228.19%
2008 83.000 275.19%
2009 140.000 40.71%
2010 28.000 -400%
2011 29.000 3.45%
2012 1.000 -2800%
2013 109.000 99.08%
2014 45.000 -142.22%
2015 20.000 -125%
2016 3.000 -566.67%
2017 37.000 91.89%
2018 0 0%
2019 36.000 100%
2020 14.000 -157.14%
2021 10.000 -40%
2022 2.000 -400%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Mymetics Corporation Equity
Year Equity Growth
1998 1.830.000
1999 2.630.000 30.42%
2000 106.474 -2370.09%
2001 694.576 84.67%
2002 -2.350.977 129.54%
2003 -4.392.574 46.48%
2004 -3.273.824 -34.17%
2005 -4.035.802 18.88%
2006 -4.027.880 -0.2%
2007 -2.539.091 -58.63%
2008 -9.315.000 72.74%
2009 -18.815.000 50.49%
2010 -21.367.000 11.94%
2011 -28.339.000 24.6%
2012 -33.235.000 14.73%
2013 -27.097.000 -22.65%
2014 -30.089.000 9.94%
2015 -32.892.000 8.52%
2016 -38.779.000 15.18%
2017 -42.878.000 9.56%
2018 -47.025.000 8.82%
2019 -51.198.000 8.15%
2020 -55.352.000 7.5%
2021 -60.086.000 7.88%
2022 -64.896.000 7.41%
2023 -75.570.000 14.12%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Mymetics Corporation Assets
Year Assets Growth
1998 2.800.000
1999 2.660.000 -5.26%
2000 220.401 -1106.89%
2001 1.694.856 87%
2002 477.437 -254.99%
2003 366.047 -30.43%
2004 123.930 -195.37%
2005 106.383 -16.49%
2006 223.518 52.41%
2007 192.043 -16.39%
2008 674.000 71.51%
2009 14.757.000 95.43%
2010 13.311.000 -10.86%
2011 9.483.000 -40.37%
2012 9.346.000 -1.47%
2013 13.120.000 28.77%
2014 11.010.000 -19.16%
2015 11.708.000 5.96%
2016 8.340.000 -40.38%
2017 8.042.000 -3.71%
2018 7.808.000 -3%
2019 7.682.000 -1.64%
2020 8.096.000 5.11%
2021 7.632.000 -6.08%
2022 7.321.000 -4.25%
2023 100.000 -7221%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Mymetics Corporation Liabilities
Year Liabilities Growth
1998 970.000
1999 30.000 -3133.33%
2000 113.927 73.67%
2001 1.000.279 88.61%
2002 2.828.414 64.63%
2003 4.758.621 40.56%
2004 3.397.754 -40.05%
2005 4.142.184 17.97%
2006 4.251.398 2.57%
2007 2.731.134 -55.66%
2008 9.989.000 72.66%
2009 33.572.000 70.25%
2010 34.678.000 3.19%
2011 37.822.000 8.31%
2012 42.581.000 11.18%
2013 40.217.000 -5.88%
2014 41.099.000 2.15%
2015 44.600.000 7.85%
2016 47.119.000 5.35%
2017 50.920.000 7.46%
2018 54.833.000 7.14%
2019 58.880.000 6.87%
2020 63.448.000 7.2%
2021 67.718.000 6.31%
2022 72.217.000 6.23%
2023 75.670.000 4.56%

Mymetics Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.04
Price to Earning Ratio
-0.03x
Price To Sales Ratio
0.77x
POCF Ratio
-0.16
PFCF Ratio
-0.16
Price to Book Ratio
-0
EV to Sales
209.44
EV Over EBITDA
-30.67
EV to Operating CashFlow
-43.34
EV to FreeCashFlow
-43.34
Earnings Yield
-39.97
FreeCashFlow Yield
-6.28
Market Cap
0,00 Bil.
Enterprise Value
0,08 Bil.
Graham Number
0.45
Graham NetNet
-0.25

Income Statement Metrics

Net Income per Share
-0.04
Income Quality
0.15
ROE
0.16
Return On Assets
-87.99
Return On Capital Employed
0.01
Net Income per EBT
1
EBT Per Ebit
13.09
Ebit per Revenue
-2.82
Effective Tax Rate
-0.07

Margins

Sales, General, & Administrative to Revenue
5.19
Research & Developement to Revenue
1.43
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.07
Operating Profit Margin
-2.82
Pretax Profit Margin
-36.92
Net Profit Margin
-36.92

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
6.11
Return on Tangible Assets
-110.68
Days Sales Outstanding
13.19
Days Payables Outstanding
143.08
Days of Inventory on Hand
0
Receivables Turnover
27.67
Payables Turnover
2.55
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,25
Tangible Book Value per Share
-0.25
Shareholders Equity per Share
-0.25
Interest Debt per Share
0.26
Debt to Equity
-0.99
Debt to Assets
751.11
Net Debt to EBITDA
-30.56
Current Ratio
0
Tangible Asset Value
-0,08 Bil.
Net Current Asset Value
-0,08 Bil.
Invested Capital
-0.99
Working Capital
-0,08 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
271.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Mymetics Corporation Dividends
Year Dividends Growth

Mymetics Corporation Profile

About Mymetics Corporation

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

CEO
Mr. Ronald Kempers
Employee
2
Address
BiopOle Center
Epalinges, 1066

Mymetics Corporation Executives & BODs

Mymetics Corporation Executives & BODs
# Name Age
1 Mr. Ronald Kempers
Chief Executive Officer, Chief Operating Officer, President & Chief Financial Officer
70
2 Dr. Sylvain Fleury
Chief Scientific Officer
70
3 Dr. Antonius Johanne Stegmann
Head of R&D and Chief Scientific Officer of Mymetics BV
70
4 Mr. Mario Amacker Ph.D.
Head of Quality & Manufacturing
70

Mymetics Corporation Competitors